Table of Content



Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Technology
1.2.2. Workflow
1.2.3. Application
1.2.4. End Use
1.3. Information analysis
1.4. Market formulation & data visualization
1.5. Data validation & publishing
1.6. Information Procurement
1.6.1. Primary Research
1.7. Information or Data Analysis
1.8. Market Formulation & Validation
1.9. Market Model
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Reduction in costs for genetic sequencing
3.2.1.2. Advances in the field of personalized medicine
3.2.1.3. Increase in prevalence of cancer
3.2.2. Market restraint analysis
3.2.2.1. Lack of computational efficiency for data management
3.3. U.S. Clinical Oncology NGS Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. U.S. Clinical Oncology Next Generation Sequencing Market: Technology Estimates & Trend Analysis
4.1. Technology Segment Dashboard
4.2. U.S. Clinical Oncology NGS Market Technology Movement Analysis
4.3. U.S. Clinical Oncology NGS Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
4.4. Whole Genome Sequencing
4.4.1. Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
4.5. Whole Exome Sequencing
4.5.1. Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
4.6. Targeted Sequencing & Resequencing
4.6.1. Targeted Sequencing & Resequencing Market, 2018 - 2030 (USD Million)
Chapter 5. U.S. Clinical Oncology Next Generation Sequencing Market: Workflow Estimates & Trend Analysis
5.1. Workflow Segment Dashboard
5.2. U.S. Clinical Oncology NGS Market Workflow Movement Analysis
5.3. U.S. Clinical Oncology NGS Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
5.4. NGS Pre-Sequencing
5.4.1. NGS Pre-Sequencing Market, 2018 - 2030 (USD Million)
5.5. NGS Sequencing
5.5.1. NGS Sequencing Market, 2018 - 2030 (USD Million)
5.6. NGS Data Analysis
5.6.1. NGS Data Analysis Market, 2018 - 2030 (USD Million)
Chapter 6. U.S. Clinical Oncology Next Generation Sequencing Market: Application Estimates & Trend Analysis
6.1. Application Segment Dashboard
6.2. U.S. Clinical Oncology NGS Market Application Movement Analysis
6.3. U.S. Clinical Oncology NGS Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
6.4. Screening
6.4.1. Screening U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
6.4.2. Sporadic Cancer
6.4.2.1. Sporadic cancer screening U.S. clinical Oncology NGS Market ,2018 - 2030 (USD Million)
6.4.3. Inherited cancer
6.4.3.1. Inherited cancer screening U.S. clinical Oncology NGS Market ,2018 - 2030 (USD Million)
6.5. Companion Diagnostics
6.5.1. Companion diagnostics U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
6.6. Other Diagnostics
6.6.1. Other diagnostics U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
Chapter 7. U.S. Clinical Oncology Next Generation Sequencing Market: End Use Estimates & Trend Analysis
7.1. End Use Segment Dashboard
7.2. U.S. Clinical Oncology NGS Market End Use Movement Analysis
7.3. U.S. Clinical Oncology NGS Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
7.4. Hospitals
7.4.1. Hospitals U.S. Clinical Oncology NGS Market, 2018 - 2030 (USD Million)
7.5. Clinics
7.5.1. Clinics U.S. Clinical Oncology NGS Market, 2018 - 2030 (USD Million)
7.6. Laboratories
7.6.1. Laboratories U.S. Clinical Oncology NGS Market, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Profiles/Listing
8.3.1. Illumina, Inc.
8.3.1.1. Overview
8.3.1.2. Financial Performance
8.3.1.3. Product Benchmarking
8.3.1.4. Strategic Initiatives
8.3.2. Thermo Fisher Scientific Inc.
8.3.2.1. Overview
8.3.2.2. Financial Performance
8.3.2.3. Product Benchmarking
8.3.2.4. Strategic Initiatives
8.3.3. F. Hoffmann-La Roche Ltd
8.3.3.1. Overview
8.3.3.2. Financial Performance
8.3.3.3. Product Benchmarking
8.3.3.4. Strategic Initiatives
8.3.4. Agilent Technologies, Inc.
8.3.4.1. Overview
8.3.4.2. Financial Performance
8.3.4.3. Product Benchmarking
8.3.4.4. Strategic Initiatives
8.3.5. Myriad Genetics, Inc.
8.3.5.1. Overview
8.3.5.2. Financial Performance
8.3.5.3. Product Benchmarking
8.3.5.4. Strategic Initiatives
8.3.6. Beijing Genomics Institute (BGI)
8.3.6.1. Overview
8.3.6.2. Financial Performance
8.3.6.3. Product Benchmarking
8.3.6.4. Strategic Initiatives
8.3.7. QIAGEN
8.3.7.1. Overview
8.3.7.2. Financial Performance
8.3.7.3. Product Benchmarking
8.3.7.4. Strategic Initiatives
8.3.8. Perkin Elmer, Inc.
8.3.8.1. Overview
8.3.8.2. Financial Performance
8.3.8.3. Product Benchmarking
8.3.8.4. Strategic Initiatives
8.3.9. PacBio
8.3.9.1. Overview
8.3.9.2. Financial Performance
8.3.9.3. Product Benchmarking
8.3.9.4. Strategic Initiatives
8.3.10. Oxford Nanopore Technologies
8.3.10.1. Overview
8.3.10.2. Financial Performance
8.3.10.3. Product Benchmarking
8.3.10.4. Strategic Initiatives
8.3.11. PerkinElmer Inc
8.3.11.1. Overview
8.3.11.2. Financial Performance
8.3.11.3. Product Benchmarking
8.3.11.4. Strategic Initiatives
8.3.12. Macrogen, Inc
8.3.12.1. Overview
8.3.12.2. Financial Performance
8.3.12.3. Product Benchmarking
8.3.12.4. Strategic Initiatives



List of Figures

List of Figures

FIG. 1 Market snapshot
FIG. 2 Market research process
FIG. 3 Information procurement
FIG. 4 Primary research pattern
FIG. 5 Market research approaches
FIG. 6 Market trends & outlook
FIG. 7 Market segmentation & scope
FIG. 8 Market driver relevance analysis (Current & future impact)
FIG. 9 Market restraint relevance analysis (Current & future impact)
FIG. 10 PESTLE Analysis
FIG. 11 Porter’s Five Forces Analysis
FIG. 12 Strategy framework
FIG. 13 Participant categorization
FIG. 14 U.S. clinical oncology NGS market: Technology outlook key takeaways
FIG. 15 U.S. clinical oncology NGS market: Technology movement analysis
FIG. 16 Whole genome sequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
FIG. 17 Whole exome sequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
FIG. 18 Targeted sequencing and resequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
FIG. 19 U.S. clinical oncology NGS market: Workflow outlook key takeaways
FIG. 20 U.S. clinical oncology NGS market: Workflow movement analysis
FIG. 21 NGS pre-sequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
FIG. 22 NGS sequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
FIG. 23 NGS data analysis for U.S. clinical oncology market, 2018 - 2030 (USD Million)
FIG. 24 U.S. clinical oncology NGS market: Application outlook key takeaways
FIG. 25 U.S. clinical oncology NGS market: Application movement analysis
FIG. 26 Screening clinical oncology NGS market, 2018 - 2030 (USD Million)
FIG. 27 Sporadic cancer screening U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
FIG. 28 Inherited cancer screening U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
FIG. 29 Companion diagnostics U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
FIG. 30 Other diagnostics U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
FIG. 31 U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
FIG. 32 Key companies profiled

List of Tables

List of Tables

TABLE 1 Cancer Incidence and Mortality, 2018
TABLE 2 U.S. clinical Oncology NGS Market estimates & forecasts
TABLE 3 U.S. clinical Oncology NGS Market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
TABLE 4 U.S. clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 5 U.S. clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 6 U.S. clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)